AR080810A1 - Composicion de un peptido a beta1-6 enlazado a una particula tipo virus, vacuna y uso - Google Patents

Composicion de un peptido a beta1-6 enlazado a una particula tipo virus, vacuna y uso

Info

Publication number
AR080810A1
AR080810A1 ARP110101001A ARP110101001A AR080810A1 AR 080810 A1 AR080810 A1 AR 080810A1 AR P110101001 A ARP110101001 A AR P110101001A AR P110101001 A ARP110101001 A AR P110101001A AR 080810 A1 AR080810 A1 AR 080810A1
Authority
AR
Argentina
Prior art keywords
agents
virus
peptide
vaccine
composition
Prior art date
Application number
ARP110101001A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42285305&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR080810(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR080810A1 publication Critical patent/AR080810A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicacion 1: Una composicion que comprende: i) una construccion que comprende el péptido Abeta1-6 enlazado a una partícula tipo virus, y ii) un adyuvante farmacéuticamente aceptable. Reivindicacion 6: Una composicion de acuerdo con la reivindicacion 5, en donde la partícula tipo virus (VLP) es a partir del bacteriofago de ARN Qbeta; el péptido Abeta1-6 se fusiona en su término C con el espaciador GGC; y en donde la partícula tipo virus (VLP) se acopla químicamente al péptido Abeta1-6 con un enlazador bivalente. Reivindicacion 8: Una vacuna de la reivindicacion 7, en donde el adyuvante es una sal de aluminio o MF59. Reivindicacion 15: Una combinacion que comprende una composicion de acuerdo con cualquiera de las reivindicaciones 1 a 6, o una vacuna de acuerdo con cualquiera de las reivindicaciones 7 a 14, y cuando menos un agente seleccionado a partir de la lista de agentes nootropicos, memantina, agentes antidepresivos, agentes antipsicoticos, agentes antidiabéticos, agentes antioxidantes, agentes anti-inflamatorios, agentes reductores de lípido, agentes de sustitucion de hormonas, agentes reductores de amiloides, inhibidores de acumulacion, quelantes, y agentes inmunomoduladores. Reivindicacion 17: Una composicion de acuerdo con cualquiera de las reivindicaciones 1 a 6, una vacuna de acuerdo con cualquiera de las reivindicaciones 7 a 14, o una combinacion de acuerdo con la reivindicacion 15, para utilizarse en el tratamiento y/o la prevencion de demencia, enfermedad de Alzheimer, demencia asociada con enfermedad de Alzheimer, o trastornos relacionados con la misma.
ARP110101001A 2010-03-29 2011-03-28 Composicion de un peptido a beta1-6 enlazado a una particula tipo virus, vacuna y uso AR080810A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10158273 2010-03-29
US36169710P 2010-07-06 2010-07-06

Publications (1)

Publication Number Publication Date
AR080810A1 true AR080810A1 (es) 2012-05-09

Family

ID=42285305

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101001A AR080810A1 (es) 2010-03-29 2011-03-28 Composicion de un peptido a beta1-6 enlazado a una particula tipo virus, vacuna y uso

Country Status (23)

Country Link
US (4) US20130011431A1 (es)
EP (1) EP2552489A1 (es)
JP (2) JP6088422B2 (es)
KR (1) KR20130018407A (es)
CN (2) CN104436212A (es)
AR (1) AR080810A1 (es)
AU (1) AU2011234656B2 (es)
BR (1) BR112012024708A2 (es)
CA (1) CA2793580A1 (es)
CL (1) CL2012002685A1 (es)
CO (1) CO6630127A2 (es)
EC (1) ECSP12012180A (es)
GT (1) GT201200265A (es)
IL (1) IL221540B (es)
MA (1) MA34084B1 (es)
MX (1) MX2012011340A (es)
NZ (1) NZ601729A (es)
PE (1) PE20130642A1 (es)
RU (1) RU2603486C2 (es)
SG (2) SG183806A1 (es)
TN (1) TN2012000431A1 (es)
TW (2) TW201138805A (es)
WO (1) WO2011120924A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
ES2953381T3 (es) 2014-04-29 2023-11-13 Advantage Therapeutics Inc Tratamiento y prevención de la enfermedad de Alzheimer (AD)
CN106659738B (zh) * 2014-04-29 2021-02-09 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
FI3137094T3 (fi) 2014-04-29 2023-03-20 Advantage Therapeutics Inc Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen
WO2015165971A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
CA2295740A1 (en) * 1997-07-08 1999-01-21 Chiron Corporation Use of submicron oil-in-water emulsions with dna vaccines
EP1409013B1 (en) * 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
WO2004016282A1 (en) * 2002-07-19 2004-02-26 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
CN100409896C (zh) * 2003-03-31 2008-08-13 姚志彬 一种老年性痴呆疫苗及其制备方法
NZ554387A (en) * 2004-09-21 2009-09-25 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CN101318015A (zh) * 2008-06-25 2008-12-10 中山大学 老年性痴呆重组蛋白疫苗及其制备方法

Also Published As

Publication number Publication date
NZ601729A (en) 2013-10-25
AU2011234656B2 (en) 2013-08-01
CN102834118A (zh) 2012-12-19
PE20130642A1 (es) 2013-06-19
CL2012002685A1 (es) 2013-01-25
JP6088422B2 (ja) 2017-03-01
RU2012145734A (ru) 2014-05-10
US20140348871A1 (en) 2014-11-27
TN2012000431A1 (en) 2014-01-30
MX2012011340A (es) 2012-11-16
US20160101167A1 (en) 2016-04-14
IL221540B (en) 2018-11-29
KR20130018407A (ko) 2013-02-21
JP2013523682A (ja) 2013-06-17
RU2603486C2 (ru) 2016-11-27
AU2011234656A1 (en) 2012-10-11
EP2552489A1 (en) 2013-02-06
SG10201505374TA (en) 2015-08-28
SG183806A1 (en) 2012-10-30
BR112012024708A2 (pt) 2016-06-07
US20130011431A1 (en) 2013-01-10
MA34084B1 (fr) 2013-03-05
CN104436212A (zh) 2015-03-25
TW201138805A (en) 2011-11-16
US20150297692A1 (en) 2015-10-22
GT201200265A (es) 2014-03-14
ECSP12012180A (es) 2012-10-30
WO2011120924A1 (en) 2011-10-06
JP2017008035A (ja) 2017-01-12
CO6630127A2 (es) 2013-03-01
TW201618806A (zh) 2016-06-01
CA2793580A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
AR080810A1 (es) Composicion de un peptido a beta1-6 enlazado a una particula tipo virus, vacuna y uso
AR089578A1 (es) Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
CO6361900A2 (es) Composicion farmaceutica de un potente de hcv para su administración oral
CO7240414A2 (es) Preparación y usos de ácido obeticólico
CO6670589A2 (es) Compuestos para reducir la producción de beta-amiloide
UY32833A (es) Antagonistas dp2 y usos del mismo
CO6571891A2 (es) Inhibidores del virus de la hepatitis c.
GT201200281A (es) Formas de dosificación sólidas orales con dosis muy bajas para la hrt
ECSP11010948A (es) Inhibidores de las enzimas de proteína cinasa activadas por
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
AR065278A1 (es) Sales de derivado de benzotiazol
GT201400069A (es) Composiciones farmaceuticas
NI201400068A (es) Formulaciones de (+) - 2 - [ 1 - (3 - etoxi - 4 - metoxi - fenil) - 2 - metanosulfonil - etil ] - 4 - acetil aminoisoindolina - 1, 3 - diona
JP2016502551A5 (es)
ECSP13012847A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación.
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
CL2015001615A1 (es) Una composicion farmaceutica que comprende vortioxetina y donepezilo junto con un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de disfuncion cognitiva, demencia en la enfermedad de alzheimer, disfuncion cognitiva asociada a la depresion y a la esquizofrenia, entre otras enfermedades.
CL2013001877A1 (es) Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus.
JP2013523682A5 (es)
CL2013003646A1 (es) Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros.
CL2022001389A1 (es) Derivado de cicloalquilurea
AR075179A1 (es) Formulaciones galenicas de compuestos organicos que comprenden alisquireno
AR087787A1 (es) Compuesto de benzotiazolona

Legal Events

Date Code Title Description
FA Abandonment or withdrawal